

DATE: November 6, 2009

TO: School of Medicine Faculty
School of Medicine DFAs

FROM: Harry Greenberg, M. D., Senior Associate Dean for Research
Marcia Cohen, Senior Associate Dean for Finance and Administration

SUBJECT: Indirect cost rate for industry funded Clinical Trials

Effective January 1, 2010, the indirect cost rate for industry sponsored clinical trials will increase from 25% to 28%. This rate will be applied to new studies received in the Research Management Group on or after January 1, 2010. Studies currently in the budgeting process in RMG or previously awarded by OSR at the 25% rate will retain the 25% F&A rate for the life of the study. (Note, the Clinical Trial definition is available at <http://rph.stanford.edu/3-2.html> section 3.A.) The new rate is based on information about industry-sponsored clinical trial IDC rates collected in the Fall-Winter of 2008-09 from about 70 other medical institutions. The survey indicated rates ranged from 25% to 60.1%.

If you have any questions, please contact your Clinical Trial RPM (see <http://med.stanford.edu/rmg/rpmmaster.html>) or Debbie Leong-Childs, Associate Director, in the Research Management Group.

CC: Ann Arvin, Dean of Research
Anne Hannigan, ORA
Barbara Cole, OSR
Kathleen Thompson, RMG
Thomas Wong, CMA